Literature DB >> 23913222

Choline metabolic profiling by magnetic resonance spectroscopy.

Egidio Iorio1, Alessandro Ricci, Maria Elena Pisanu, Marina Bagnoli, Franca Podo, Silvana Canevari.   

Abstract

The revised version of cancer hallmarks, depicting the biological properties acquired during tumor development and progression, includes the capability to modify or reprogram cellular metabolism. High-resolution multinuclear magnetic resonance spectroscopy (MRS) provides noninvasive means of monitoring metabolites that play a central role in several pathways, measuring the rates at which reactions within the pathways take place, and investigating how these rates are controlled in such a way that a metabolic precursor and cofactors are provided according to the demand. Here we describe comprehensive methods for assaying the activity of key enzymes involved in the phosphatidylcholine metabolic pathways responsible for phosphocholine accumulation in ovarian cancer cells using high-resolution (1)H and (31)P MRS analyses of cell lysates or cytosolic preparations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913222     DOI: 10.1007/978-1-62703-547-7_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.

Authors:  Anna Granata; Roberta Nicoletti; Paola Perego; Egidio Iorio; Balaji Krishnamachary; Fabio Benigni; Alessandro Ricci; Franca Podo; Zaver M Bhujwalla; Silvana Canevari; Marina Bagnoli; Delia Mezzanzanica
Journal:  Oncotarget       Date:  2015-05-10

2.  Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells.

Authors:  Laura Mercurio; Serena Cecchetti; Alessandro Ricci; Aurora Pacella; Giovanni Cigliana; Giuseppina Bozzuto; Franca Podo; Egidio Iorio; Giulia Carpinelli
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

3.  Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.

Authors:  A Granata; R Nicoletti; V Tinaglia; L De Cecco; M E Pisanu; A Ricci; F Podo; S Canevari; E Iorio; M Bagnoli; D Mezzanzanica
Journal:  Br J Cancer       Date:  2013-11-26       Impact factor: 7.640

4.  Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.

Authors:  Luisa Paris; Franca Podo; Egidio Iorio; Rossella Canese; Francesca Spadaro; Laura Abalsamo; Maria Elena Pisanu; Alessandro Ricci; Serena Cecchetti; Luisa Altabella; Maria Buoncervello; Ludmila Lozneanu; Marina Bagnoli; Carlo Ramoni; Silvana Canevari; Delia Mezzanzanica
Journal:  Oncotarget       Date:  2017-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.